Interleukin-17 receptor C homodimer (IL-17RC)

Interleukin-17 receptor C (IL-17RC) is a single-pass type I transmembrane protein and a key member of the IL-17 receptor family [7, 9]. While it typically forms a heterodimer with IL-17RA to mediate signaling for IL-17A and IL-17F, recent structural studies have demonstrated that IL-17F can also signal through an IL-17RC homodimer (a 2:1 receptor-to-ligand complex), enabling IL-17RA-independent pathways [4, 37]. IL-17RC is predominantly expressed in non-hematopoietic tissues such as epithelial cells and fibroblasts, where it is essential for host defense against extracellular pathogens, particularly Candida albicans [2, 5]. In the context of oncology, IL-17RC homodimers are overexpressed in certain cancers, such as prostate cancer, where they promote cell survival by inhibiting TNF-alpha-induced apoptosis [2, 9]. Dysregulation of IL-17RC-mediated signaling is a driver of chronic inflammatory and autoimmune diseases, including psoriasis and rheumatoid arthritis [2, 16]. Although current clinical therapies like bimekizumab, secukinumab, and brodalumab target the IL-17 ligands or the IL-17RA subunit, IL-17RC remains a significant therapeutic target for more selective immune modulation, with soluble decoy receptors and specific antagonists under investigation [3, 7, 32].

Other names

IL17RCIL-17RLZcytoR14CANDF9Interleukin-17 receptor-like protein

Ligand neutralization (IL-17A/F) and receptor signaling antagonism [16, 31].